15.01.2024 – 07:30
Perfood GmbH
Lübeck (ots)
With glucura, people with type 2 diabetes mellitus now have access to an innovative digital health application (DiGA) that is available with a prescription. glucura has been approved as DiGA by the Federal Institute for Drugs and Medical Devices (BfArM) and can be prescribed to people with type 2 diabetes mellitus. The new DiGA sets standards in diabetes management because, for the first time, it uses individual glucose reactions to give those affected personalized nutritional recommendations. With the help of artificial intelligence, users receive lifestyle recommendations tailored to their needs and are guided step by step to effectively and permanently lower their blood sugar levels. Glucura’s multimodal therapeutic approach transfers the findings from personalized nutritional therapy, exercise therapy and behavioral intervention into a sustainable digital health application. glucura is aimed at people with non-insulin-treated type 2 diabetes mellitus aged 18 and over and is available with the operating systems Apple iOS from version 14.0 and Google Android from version 8.0.
The German Diabetes Health Report (2023) estimates the number of documented cases of type 2 diabetes mellitus in 2022 to be 8.7 million affected. In addition, there is an unreported number of around two million people who are already ill without knowing it. Based on the total population in Germany, around ten percent of adults have type 2 diabetes mellitus. As life expectancy increases, experts predict a 59 percent increase in cases from 2020 to 2040. The disease can be accompanied by sometimes serious accompanying and secondary diseases, which affect, among other things, the vessels, heart, kidneys, nerves and eyes. For example, those affected have a much increased risk of heart attack and stroke.
In a clinical trial[1] Patients with type 2 diabetes mellitus were able to significantly improve their long-term blood sugar levels using glucura, which is known in technical jargon as the “HbA1c value”. The HbA1c decreased by -0.79% points after 3 months of glucura use compared to standard treatment (n= 64 people). Using glucura, 61 percent were twice as many patients in the therapeutic target range of below 7.0 percent HbA1c as before the start of use. 34 percent of them even achieved an HbA1c below 6.5 percent, which is defined as the normal metabolic range. In general, the lower the HbA1c proportion, the better the diabetes is controlled, because the less blood sugar is bound to the red blood pigment hemoglobin. In addition, the body mass index (BMI) decreased by more than one point (-1.25 kg/m2). Those affected also reported that they used glucura frequently (6.6 out of 7 days per week) and that the program was easy to understand (4.5/5). In addition to the high level of satisfaction (7.7/10), it was emphasized that it provides good support in dealing with the disease (4.1/5) and that they would like to continue therapy with glucura (3.9/5 )[2].
[1] Scientific evaluation concept glucura from November 29, 2023
[2] The mean values of the surveys after one month are given in each case
Press contact:
Perfood GmbH
Ulrike Voss
Am Spargelhof 2
23554 Lübeck
[email protected]
0172 – 590 55 50
Original content from: Perfood GmbH, transmitted by news aktuell